This review posits that the answer lies with a single, indispensable protagonist: the Phosphoinositide 3-kinase (PI3K)/Protein Kinase B (Akt)/mammalian Target of Rapamycin (mTOR) signaling pathway, which serves as the critical nexus between systemic metabolic dysfunction and the local tumor immuno-metabolic landscape. This evidence concerns the gene AKT1 and neoplasm.